Momenta says planned runs at manufacturing partner GSK could be reattributed to another product as it ends development of M923, a biosimilar candidate to Humira (adalimumab).
In October 2018, Momenta Pharmaceuticals said it was exiting the biosimilars space following a lengthy strategic review process to concentrate on its novel biologics pipeline. The company told Scrip it would terminate all but two late-stage programs, a biosimilar version of AbbVie’ blockbuster Humira (adalimumab) and a biosimilar of Regeneron’s Eylea (aflibercept).
Ten months on, and the firm has now made the decision to drop the adalimumab program M923.
Image: AdobeStock/iushakovsky
“We have previously said that we would not be taking this program forward ourselves,†CEO Craig Wheeler told stakeholders on a financial call this month. “While we were hopeful that we could secure a commercial partner for this program, and we did have interest as we pursued the path, the market opportunity has changed significantly with recent settlements, ensuring that up to eight players will be launching at once.â€
Humira pulled in sales of $19.9 billion (€17.8 billion) for AbbVie in 2018, but legal agreements between the originator firm and a host of biosimilar developers will keep direct competition off the US market until 2023. This is when versions made by Amgen, Boehringer Ingelheim, Sandoz and Samsung Bioepis are set to launch in the US, and with other biosimilars likely to receive US Food and Drug Administration (FDA) approval, the market could be saturated.
Cost savings and GSK costs
Without a commercial partner for M923, Wheeler said “it is prudent to cease ongoing investment.â€
The decision will save approximately $100 million in anticipated costs to launch the product, which will now be allocated to Momenta’s novel programs, he added.
However, the decision to end the program does have repercussions with Momenta’s M923 supplier GSK, as the firm will no longer utilize scheduled manufacturing runs at the contract manufacturing organization (CMO) originally scheduled for 2020.
“However, these trigger the take-or-pay provisions of our contract, which requires us to pay GSK a contractually agreed-to fee at the time the runs in 2020 and 2022 would have been completed,†Wheeler said.
“Together, they [GSK] require us to incur a onetime charge in our Q2 financials as reported.†This equates to a $42.9 million charge to be paid between the end of 2020 and 2022.
No decisions have yet been made on the scheduled 2022 manufacturing runs but Wheeler said there is “flexibility in the contract†and the runs could be used to produce for another project.
Eylea
Momenta will continue advancing M710, its proposed biosimilar to Eylea, which it is codeveloping with partner Mylan.
“Mylan is currently enrolling patients in the Phase 3 study to this product, and we continue to believe that we have the opportunity to launch in the US as early as 2023,†Wheeler said.
“We are currently in the lead for developing this asset and believe M710 could bring in significant revenue to support our expanding novel pipeline and we look forward to keeping you update here as this trial progresses.â€
Related news: ‘Pro-biosimilar policies will not ignite US market, Amgen’
Related news: ‘Bye bye biosimilars: Big Pharma’s imminent exit in sight, says expert’